Re: [MOL] Up date on cancer research [01454] Medicine On Line

[Date Prev][Date Next][Thread Prev][Thread Next][Date Index][Thread Index]

Re: [MOL] Up date on cancer research

DEar JOhn,

Not too encouraging is it? HOwever, I am encouraged to know that there
will be some company or someone out there, maybe in other countries as
they often do, to jump on the bandwagon and produce this drug in large
quantities for testing. I know much is going on in Europe with similar
drugs. thanks for info Brother.

God Bless

John wrote:
> Dear friends,
> While I have been away for some time, I have never left the spirit of
> mol-cancer and keep you all in my prayers.  I thought you may be
> interested in the piece in the NY Times today.  When you read the full
> text, you begin to see how research works and begin to temper what you
> read in the news and to discount much of the 30 second news bites that
> we
> are all bombarded with.  There is clearly no miracle cure for this
> monster yet hope that progress will continue in developing means to
> limit
> and treat those of us bearing this journey.
> I hope to be able to return soon...though I am terrified of the volume
> of
> mail being generated daily.  It seems too much like a full time job to
> keep up and support those new people looking for help.  I am sure that
> my
> dear Auntie Lil, sister Carla, and brother Marty are all in there
> plugging away.  My Love and prayers are with you.
> John
>     ---------------------------------------------------------------
>         [banner]
>         [toolbar]
>         [Intrigue by Oldsmobile]
>           February 10, 1999
>           Company Is Stopping Its Work on a Prominent Cancer
>           Drug
>           By DAVID J. MORROW
>               he Bristol-Myers Squibb Company, a leading
>               maker of anti-cancer drugs, said Tuesday that
>           it was halting its work on angiostatin, one of two
>           anti-cancer compounds that had excited intense
>           interest in the last year or so.
>           Company officials hesitated to provide details for
>           the decision. But Robert A. Kramer, vice president
>           for oncology drug discovery, said in a statement:
>           "At this time, angiostatin protein in its present
>           form does not meet our criteria for molecules that
>           advance to clinical trials. We have chosen to
>           direct our resources to other programs in our
>           broad oncology pipeline."
>           In an interview later, Kramer said the company's
>           main concern was not the compound's effectiveness,
>           but rather whether it could be manufactured in
>           large enough amounts in sufficient strength to
>           sustain tests in people.
>           In a news release issued by Bristol-Myers Squibb
>           and Entremed, the small biomedical company in
>           Rockville, Md., that has been its partner in the
>           work, the two companies said the development
>           agreement between them was being modified.
>           While Entremed will continue to develop
>           angiostatin, the statement said, Bristol-Myers
>           Squibb will retain the option to reassume
>           development and marketing rights of the protein
>           once "clinical proof of principal has been
>           demonstrated."
>           Entremed first captured national attention last
>           May when a front-page article in The New York
>           Times reported enthusiasm among scientists that
>           angiostatin and endostatin, another compound being
>           tested by the company, made tumors disappear in
>           mice.
>           Since then, there have been reports that
>           scientists have had difficulty working with the
>           compounds, whose use as cancer treatments was
>           initially investigated by Dr. Judah Folkman, a
>           researcher at Harvard University.
>           The reports have frustrated John Holaday,
>           Entremed's chief executive, who called the media
>           attention surrounding Tuesday's announcement a
>           non-event. Holaday emphasized that Bristol-Myers
>           Squibb would still consult during the development
>           of angiostatin and that the two companies'
>           agreement was anything but ended.
>           "In developing this drug, we have come under a
>           tremendous spotlight," Holaday said. "We had
>           planned to quietly develop the drugs with haste to
>           get them to cancer patients. But we were
>           catapulted into the spotlight with that New York
>           Times article. Now everything we do gets news
>           whether its newsworthy or not."
>           The article turned angiostatin into one of the
>           year's hottest drugs even though it had yet to be
>           tested on humans and was years away from being
>           released. Entremed's stock jumped $39.75, to
>           $51.81, with the trading volume at a level above
>           the number of shares outstanding.
>           But the article reported excitement among
>           scientists about earlier findings, not about new
>           results. As Holaday noted Tuesday, there had been
>           no new developments regarding the compounds for
>           several months.
>           As planned, Entremed said Tuesday, it should begin
>           angiostatin's clinical trials on humans this year.
>           Until those trials are under way, no one will know
>           how successful angiostatin can be.
>           Official at Bristol-Myers Squibb also emphasized
>           that the company's decision to have Entremed
>           develop angiostatin had nothing to do with the
>           drug's effectiveness or doubts the company had on
>           whether it could be safety used in humans.
>           "We have confidence in the principle of
>           angiostatin," said Kramer, the company vice
>           president. "We are confident that the angiostatin
>           molecule can reduce tumors in mice. You just have
>           to understand that angiostatin has to be one of
>           the most complex compounds ever to be developed
>           for man."
>                                  [Image]
>         -----------------------------------------------------------
>           Home | Site Index | Site Search | Forums | Archives |
>                                Marketplace
>         Quick News | Page One Plus | International | National/N.Y.
>           | Business | Technology | Science | Sports | Weather |
>              Editorial | Op-Ed | Arts | Automobiles | Books |
>              Diversions | Job Market | Real Estate | Travel
>          Help/Feedback | Classifieds | Services | New York Today
>                 Copyright 1999 The New York Times Company
This is an automatically-generated notice.  If you'd like to be removed
from the mailing list, please visit the Medicine-On-Line Discussion Forum
at <>, or send an email message to:
with the subject line blank and the body of the message containing the line:
unsubscribe mol-cancer your-email-address
where the phrase your-email-address is replaced with your actual email